BioAscent published a new case study demonstrating how xCELLigence cellular impedance technology interrogated signalling and receptor desensitisation in GPR35b endogenously expressed in HT-29 cells.

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon / MSD R&D site in Newhouse, Scotland, UK. Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening (including HTS), medicinal and synthetic chemistry, computational chemistry and compound management, all with access to in-house diversity and fragment libraries. Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications. As part of its compound management service, BioAscent currently holds and manages over 1.5 million compounds for our customers, in both liquid and solid formats.